Immunosuppresive effects of pteridine derivatives

a technology of pteridine and derivatives, which is applied in the direction of biocide, plant growth regulators, cyclic peptide ingredients, etc., can solve the problems of high turn-over rate, marrow depression and liver damage, and severe toxic effects on normal cells

Inactive Publication Date: 2007-02-22
4 AZA IP NV
View PDF36 Cites 26 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Since these drugs affect mitosis and cell division, they have severe toxic effects on normal cells with high turn-over rate such as bone marrow cells and the gastrointestinal tract lining.
Accordingly, marrow depression and liver damage are common side effects.
The common side effects observed with the use of these compounds are frequent infections, abnormal metabolism, hypertension, and diabetes.
However, cyclosporines suffer from a small therapeutic dose window and severe toxic effects including nephrotoxicity, hepatotoxicity, hypertension, hirsutism, cancer, and neurotoxicity.
Another such drug, mitoxantrone, is known to induce heart and kidney toxicity.
Introduction of such monoclonal antibodies into a patient, as with many biological materials, induces several side-effects, such as dyspnea.
However, such ideal matches are difficult to achieve.
Further, with the increasing need of donor organs an increasing shortage of transplanted organs currently exists.
Accordingly, xenotransplantation has emerged as an area of intensive study, but faces many hurdles with regard to rejection within the recipient organism.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Immunosuppresive effects of pteridine derivatives
  • Immunosuppresive effects of pteridine derivatives
  • Immunosuppresive effects of pteridine derivatives

Examples

Experimental program
Comparison scheme
Effect test

examples 1 to 5

Preparation of Tri- and Tetra-Substituted 1,3-dimethyl-lumazines

[0215] The following tri- and tetra-substituted 1,3-dimethyl-lumazines were prepared according to methods and procedures described hereinbefore by reference to FIGS. 6 and 7: [0216] 6-[2-(p-trifluoromethylphenyl)ethenyl]-1,3-dimethyl-lumazine (example 1), [0217] 6-[2-(p-trifluoromethylphenyl)ethenyl]-1,3-dimethyl-lumazine (example 2), [0218] 6-[2-phenylethenyl]-1,3-dimethyl-lumazine (example 3), [0219] 6-[2-(p-trifluoromethoxyphenyl)ethenyl]-1,3-dimethyl-lumazine (example 4), and [0220] 6-cyano-7-ethylmercaptoacetate-1,3-dimethyl-lumazine (example 5).

example 6

Preparation of 3-methyl-6-phenyl-7-chloro-lumazine

[0221] 3-methyl-6-phenyl-7-chloro-lumazine was prepared according to the general methods described hereinbefore by reference to FIG. 6.

examples 7 to 20

Preparation of 1,6-Disubstituted 7-hydroxylumazines

[0222] In a first step, trisubstituted lumazines having the general formula (I) wherein R1 is hydrogen, R4 is hydroxyl, and R2 and R3 are as indicated in table 1 below for each of examples 7-13, were prepared according to the general methods described hereinbefore by reference to FIG. 6, in particular steps (d) and (e) thereof, and more specifically according to the following procedure:

[0223] To a suspension of a 5,6-diamino-1-substituted uracil hydrate (10 mmole) in 200 ml water, ethyl substituted benzoylformate (12.5 mmole) was added. The resulting mixture was heated under reflux for 40 minutes. After cooling to room temperature, the precipitate was collected to yield a crude product which was re-crystallized from a MeOH / water (1 / 1) mixture to yield yellowish crystals or powder of the desired 7-hydroxyl tri-substituted lumazine.

TABLE 1R2R3Examplemethylphenyl7methylp-methoxyphenyl8methylp-toluyl9phenylphenyl10benzylphenyl11meth...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
optical purityaaaaaaaaaa
optical purityaaaaaaaaaa
optical purityaaaaaaaaaa
Login to view more

Abstract

Novel poly-substituted pteridinediones (lumazines), and mono- or polysubstituted 2-thiolumazines, 4-thiolumazines or 2,4-dithiolumazines, having disclosed substituents in positions 1, 3, 6 and 7 of the pteridine ring, and pharmaceutically acceptable salts thereof, are useful as biologically active ingredients in preparing pharmaceutical compositions especially for the treatment or prevention of a CNS disorder, a cell proliferative disorder, a viral infection, an immune or auto-immune disorder or a transplant rejection. Combinations of the pteridine derivatives of the invention with an immunosuppressant or immunomodulator drug, an antineoplastic drug or an antiviral agent, providing potential synergistic effects, are also disclosed.

Description

[0001] The invention relates to a class of novel poly-substituted pteridine-2,4-diones (lumazines), as well as novel mono- and polysubstituted 2-thiolumazines, 4-thiolumazines and 2,4-dithiolumazines. The invention further relates to pharmaceutical compositions including a broad class of poly-substituted pteridine-2,4-diones (lumazines), as well as mono- and polysubstituted 2-thiolumazines, 4-thiolumazines and 2,4-dithiolumazines especially for the prevention and / or the treatment of pathologic conditions such as, but not limited to, immune and autoimmune disorders, organ and cells transplant rejections, cell proliferative disorders, cardiovascular disorders, disorders of the central nervous system and viral diseases. [0002] The invention further relates to combined pharmaceutical preparations comprising one or more polysubstituted pteridine-2,4-diones (lumazines), as well as mono- and polysubstituted 2-thiolumazines, 4-thiolumazines and 2,4-dithiolumazines and one or more known immu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/675A61K31/5377A61K31/525C07D475/04C07F9/6512A61K31/505A61K31/52A61K31/535A61K31/57A61K38/13C07D475/02
CPCA61K31/505A61K31/52A61K31/535A61K31/57A61K38/13C07D475/02C07F9/6561A61K2300/00A61P25/00A61P35/00A61P37/02A61P37/06A61P9/00
Inventor WAER, MARK JOZEF ALBERTHERDEWIJN, PIET ANDRE MAURITS MARIAPFLEIDERER, WOLFGANG EUGEN
Owner 4 AZA IP NV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products